Nasus Pharma adds CEO Dan Teleman to its board

Nasus Pharma Ltd. reported governance changes approved by its Board of Directors.

Rhea-AI Filing Summary

Nasus Pharma Ltd. reported governance changes approved by its Board of Directors. The Board appointed Chief Executive Officer Dan Teleman to also serve as a director, filling a vacancy in accordance with the company’s Amended and Restated Articles of Association.

Teleman will serve as a Class III director, with his term scheduled to expire at the annual general meeting of shareholders to be held in 2028. The Board also changed the composition of its Compensation Committee, replacing David Silberman with Ronnie Hershman as a committee member.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What governance change did Nasus Pharma (NSRX) announce in this 6-K?

Nasus Pharma announced that CEO Dan Teleman was appointed to its Board of Directors. He fills an existing vacancy under the company’s Amended and Restated Articles of Association, strengthening overlap between executive management and board-level decision-making at the company.

How long will CEO Dan Teleman serve as a director at Nasus Pharma (NSRX)?

Dan Teleman will serve as a Class III director at Nasus Pharma. His term is set to expire at the company’s annual general meeting of shareholders scheduled to be held in 2028, aligning his board role with the staggered board classification structure.

What change occurred on Nasus Pharma’s (NSRX) Compensation Committee?

Nasus Pharma’s Board decided to replace David Silberman with Ronnie Hershman as a member of the Compensation Committee. This adjustment affects oversight of executive and director pay policies, aligning committee membership with the Board’s current preferences and governance structure.

Why was Dan Teleman eligible to join the Nasus Pharma (NSRX) Board?

Dan Teleman was appointed to Nasus Pharma’s Board to fill a vacancy, as permitted by the company’s Amended and Restated Articles of Association. These governing documents authorize the Board to appoint a director when a board seat becomes open between shareholder meetings.

Does this Nasus Pharma (NSRX) 6-K discuss any financial results or transactions?

This 6-K focuses on corporate governance changes, not financial performance. It covers the appointment of CEO Dan Teleman as a director and the replacement of a Compensation Committee member, without providing earnings data or major transaction details in the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/05/2025 - 08:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On September 3, 2025, the Board of Directors (the “Board”) of Nasus Pharma Ltd. (the “Company”) appointed Dan Teleman, the Company’s Chief Executive Officer, to serve as a director on its Board. Mr. Teleman was appointed to the Board as permitted under the Company’s Amended and Restated Articles of Association due to a vacancy on the Board. Mr. Teleman will serve as a Class III director, which term will expire at the annual general meeting of shareholders to be held in 2028.

In addition to Mr. Teleman’s appointment, the Board resolved to replace David Silberman with Ronnie Hershman as a member of the Compensation Committee of the Board.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
Date: September 5, 2025	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer